| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
IND Submission example | IND | — | Subscribe to access the data. | Biologics | Nervous System | ||
IND Submission example | IND | — | Subscribe to access the data. | Biologics | Nervous System | ||
IND Submission example | IND | — | Subscribe to access the data. | Biologics | Nervous System |
Recent Updates
Recently added Catalysts
InMed Pharmaceuticals Inc.$1.64
-0.15 (-9.04%)
F 12Pipeline Score Richly Valued Pharma · Clinical
Market Cap
5.70 M
EPS
-2.58
P/E Ratio
-
Value Trade
139.05 K
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
1.02 M
Total Assets
9.13 M
Total Liabilities
2.24 M
Equity
6.89 M
D/E Ratio
12,345
159.3 %
Week
133.6 %
1 Month
99.33 %
3 Month
47.01 %
6 Month
-99.87 %
5 Year
-99.61 %
All Time
Cash Data
Cash Position
5.20 M
Monthly Burn
931.00 K
Runway
3.7 mo
Burn Trend
SEC Filing
May 6, 2026
Overview
Volume
19.07 K
52 Week Range
0.58 - 7.98
% held by Insiders
24.21 %
% held by Institutions
46.01 %
Enterprise Value
919.78 K
Total Shares
2.92 M
Short %
5.7 %
Float Shares
2.60 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for InMed Pharmaceuticals Inc.
310Total events
14Upcoming
40Tier-1 (high impact)
2020 – 2028Coverage
Upcoming catalysts 14
Event history 296
Q3 2026
▲Preclinical PoCINM-901Preclinical
Preclinical data demonstrating INM-901 reduces neuroinflammation in 3D human brain organoid models
Alzheimer's diseasesource ↗
Q3 2026
Jun 3, 2026
Jun 2026
●IND SubmissionMT-001IND
First-in-human regulatory filing for MT-001 expected mid-2026
migraine preventionsource ↗
May 19, 2026
Q2 2026
Q2 2026
●IND SubmissionMT-001IND
First-in-human regulatory filing for MT-001 (anti-PACAP)
migraine preventionsource ↗
Mar 27, 2026
Mar 23, 2026
▲Preclinical PoCINM-901Preclinical
Positive data from human brain organoid neuroinflammation models supporting INM-901
Alzheimer's diseasesource ↗
Drug Pipeline Intelligence
F12
Pipeline Score $0M
Pipeline ValueRichly Valued
Valuation Signal1
Drugs Scored0.0x
rNPV / MCap Top 9%
Micro Cap (rank 830 of 911)
Percentile RankInMed Pharmaceuticals Inc. has significant pipeline risk (12/100), with $120M risk-adjusted pipeline value, led by INM-755 in Epidermolysis Bullosa Simplex (Phase 2), but cash runway is a concern.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| INM-755 Small molecule | Epidermolysis Bullosa Simplex | Phase 2 | NCT04908215 | 17% | $120M | COMPLETED | 19 | - | - | Apr 19, 2023 | - | Jul 3, 2023 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
INM-755 | epidermolysis bullosa | Phase 2 | 2023-11-02 | positive indication of enhanced anti-itch activity for INM-755 cannabinol cream versus the control cream alone Read More | NASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Announces Presentation of INM-755 Phase 2 Clinical Study Results at 12th Read More | |
INM-755 | epidermolysis bullosa | Phase 2 | 2023-11-02 | positive indication of enhanced anti-itch activity for INM-755 cannabinol cream versus the control cream alone Read More | NASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Announces Presentation of INM-755 Phase 2 Clinical Study Results at 12th Read More | |
INM-755 | epidermolysis bullosa | Phase 2 | 2023-11-02 | positive indication of enhanced anti-itch activity for INM-755 cannabinol cream versus the control cream alone Read More | NASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Announces Presentation of INM-755 Phase 2 Clinical Study Results at 12th Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in INM
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
INM Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
INMFiled by newsfilecorp.com NASDAQ: INM Suite 1445-885 West Georgia St. Vancouver, BC, Canada V6C 3E8 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Pharmaceuticals Regains Compliance with Nasda
InMed Pharmaceuticals Inc. has announced that it has regained compliance with Nasdaq's minimum bid price requirement, as it maintained a closing bid price above $1.00 per share for 10 consecutive business days. This follows a notification from Nasdaq concerning non-compliance on March 27, 2026. The company was informed on June 3, 2026, that the compliance issue is now resolved. InMed focuses on developing small molecule drug candidates for various therapeutic indications including Alzheimer's and dermatological conditions.
Read more →INM▲ +135.1%on this news
InMed Pharmaceuticals & Mentari Therapeutics Announce Merger to Advance Migraine Prevention Therapies
InMed Pharmaceuticals has announced a merger with Mentari Therapeutics to advance migraine prevention therapies. The merger combines Mentari's innovative migraine pipeline with InMed's public market infrastructure, aiming to expedite the development of new treatments. A concurrent $290 million private placement is expected to fund operations through 2028, with regulatory filings for new therapies anticipated in mid-2026 and early 2027.
Read more →INM▲ +135.1%on this news
InMed Pharmaceuticals Amends Preferred Investment Options
InMed Pharmaceuticals has amended the exercise price of certain preferred investment options held by Armistice Capital from $16.60 to $0.80. This change may enhance the likelihood of investment by Armistice. The company is focused on developing small molecule drug candidates targeting high unmet medical needs, particularly in Alzheimer's and dermatological conditions.
Read more →INM▲ +135.1%on this newsshared move
NASDAQ: INM Suite 1445-885 West Georgia St. Vancouver, BC, Canada V6C 3E8 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Pharmaceuticals & Mentari Therapeutics Announce Merger to Advance Migra
InMed Pharmaceuticals has announced a merger with Mentari Therapeutics to advance migraine prevention therapies. The merger combines Mentari's promising migraine pipeline with InMed's market infrastructure, aiming to expedite the development of innovative treatments for migraine sufferers. A concurrent private placement has successfully raised $290 million to support operations through 2028. The combined entity will operate under the Mentari Therapeutics name and is set to trade on the Nasdaq under a new ticker symbol after the merger's completion, anticipated in the second half of 2026.
Read more →INM▲ +135.1%on this newsshared move
Filed by newsfilecorp.com NASDAQ: INM Suite 1445-885 West Georgia St. Vancouver, BC, Canada V6C 3E8 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Pharmaceuticals Amends Preferred Investment O
InMed Pharmaceuticals Inc. has amended its agreement with Armistice Capital Master Fund Ltd. regarding certain preferred investment options. The exercise price for these options has been reduced from $16.60 to $0.80. This change is part of the company's ongoing efforts to address its investment strategy while emphasizing its focus on developing small molecule drug candidates targeting CB1/CB2 receptors. The company notes that there are uncertainties regarding the exercise of these options and other risk factors that could impact its future performance.
Read more →INMFiled by newsfilecorp.com NASDAQ: INM Suite 1445-885 West Georgia St. Vancouver, BC, Canada V6C 3E8 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Reports Third Quarter Fiscal 2026 Financial R
InMed Pharmaceuticals has reported its financial results for the third quarter of fiscal 2026, concluding with a net loss of $3.0 million. The report highlighted significant preclinical advancements for INM-901, targeting neuroinflammation related to Alzheimer's disease, showcasing substantial reductions in inflammatory markers across human brain organoid models. Despite the promising development, the company announced the discontinuation of its commercial operations, which could impact revenue as resources are redirected to enhance its drug development efforts. Overall, while there are advancements, the financial losses remain a concern as the company transitions focus areas.
Read more →INM▼ -5%on this news
NASDAQ: INM Suite 1445-885 West Georgia St. Vancouver, BC, Canada V6C 3E8 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Pharmaceuticals Amends Preferred Investment Options Vancouver, BC
InMed Pharmaceuticals has announced amendments to its preferred investment options with Sabby Volatility Warrant Master Fund, Ltd. and affiliates of H.C. Wainwright & Co. The exercise prices for these options are adjusted to $0.80. The amendments come as part of the company's strategy to strengthen its financial position while focused on its pipeline of small molecule drug candidates targeting various medical conditions.
Read more →INMFiled by newsfilecorp.com NASDAQ: INM 1445 - 885 West Georgia St. Vancouver, BC, Canada V6C 3E8 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Pharmaceuticals Receives Nasdaq Notification Rega
InMed Pharmaceuticals has received a notice from Nasdaq stating that its common shares have not met the minimum bid price requirement of $1.00 per share for continued listing. The company has a period of 180 calendar days to rectify this situation and may consider options like a reverse stock split. Failure to comply may result in delisting from Nasdaq, though there's a possibility of an additional grace period if certain conditions are met. InMed is focused on developing small-molecule drug candidates aimed at CB1/CB2 receptors, with programs targeting Alzheimer's and other conditions.
Read more →INM▼ -6.9%on this news
Filed by newsfilecorp.com NASDAQ: INM 1445 - 885 West Georgia St. Vancouver, BC, Canada V6C 3E8 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Pharmaceuticals Announces Positive Data from Huma
InMed Pharmaceuticals has announced promising preclinical data demonstrating the efficacy of its drug candidate INM-901 in reducing neuroinflammation in human brain organoid models relevant to Alzheimer's disease. This new data showcases consistent anti-inflammatory effects that align with previous results from animal studies, suggesting the drug's potential translational value for human clinical applications. The organization plans to engage in regulatory discussions and aims to initiate Phase 1 clinical trials in 2027, marking significant progress in the development of treatments targeting neuroinflammation in Alzheimer's disease.
Read more →INMInMed Provides Update on Pharmaceutical Development Programs - Advancing Lead Drug Candidates Towards IND and Clinical Trial
InMed has provided an update on its pharmaceutical development programs, highlighting progress in advancing its lead drug candidates towards Investigational New Drug (IND) submission and subsequent clinical trials. This development indicates a positive trajectory for the company's research and potential market entry. The focus remains on ensuring the candidates meet regulatory standards.
Read more →INMFiled by newsfilecorp.com NASDAQ: INM 1445 - 885 West Georgia St. Vancouver, BC, Canada V6C 3E8 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Provides Update on Pharmaceutical Development Pro
InMed Pharmaceuticals has provided an update on its drug development programs, focusing on promising progress with INM-901 aimed at treating Alzheimer's disease. The company plans to hold a pre-IND meeting with the FDA in Q3 2026, paving the way for an IND submission and Phase 1 clinical trial expected to start in 2027. INM-901 has demonstrated substantial efficacy in reducing neuroinflammation and improving key biomarkers in preclinical studies. Additionally, InMed is progressing on INM-089 for treating dry age-related macular degeneration and plans to meet with the FDA in Q4 2026.
Read more →INMPro Forma Information on Continuing Operations The following unaudited pro forma consolidated financial information of InMed Pharmaceuticals Inc. (the "Company") is derived from its historical consolidated financial stat
InMed Pharmaceuticals Inc. released unaudited pro forma consolidated financial information reflecting the wind down of BayMedica LLC's commercial operations as discontinued operations. The statements for the six months ending December 31, 2025, and the year ending June 30, 2025, present estimated adjustments based on management's assumptions. These pro forma statements are for informational purposes only and do not guarantee future results. The company has not finalized fair value assessments of its assets related to the discontinued operations.
Read more →INM▼ -10.1%on this news
InMed Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update
InMed Pharmaceuticals has released its financial results for the second quarter of fiscal 2026. The report includes updates on the company's ongoing business activities and financial performance. Specific details regarding revenue, expenses, and future projections were not provided in the article.
Read more →INMFiled by newsfilecorp.com NASDAQ: INM 1445 - 885 West Georgia St. Vancouver, BC, Canada V6C 3E8 Tel: +1.604.669.7207 Email : info@inmedpharma.com www.inmedpharma.com InMed Reports Second Quarter Fiscal 2026 Financial Res
InMed Pharmaceuticals Inc. reported its financial results for the second quarter of fiscal 2026, indicating steady progress in its drug development pipeline, particularly with INM-901 targeting neuroinflammation in Alzheimer's disease. Positive preclinical data support the advancement to human clinical trials. However, revenues from the subsidiary BayMedica decreased by 26% due to pending U.S. legislation which may adversely affect its commercial business. The company remains focused on pursuing pre-IND meetings with the FDA for both its INM-901 and INM-089 drug candidates.
Read more →INM▼ -8.7%on this news
Filed by newsfilecorp.com NASDAQ: INM 1445 - 885 West Georgia St. Vancouver, BC, Canada V6C 3E8 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Announces Results of 2025 Annual General and Spec
InMed Pharmaceuticals confirmed the results of its 2025 Annual General and Special Meeting held on December 17, where significant matters were voted on by shareholders. The election of the Board of Directors received favorable votes, with all nominated individuals receiving over 81% support. Additionally, shareholders approved the selection of CBIZ CPAs P.C. as auditors and the potential issuance of new shares under an equity agreement. Overall, the meeting reflects positive shareholder engagement and future corporate governance commitments.
Read more →INMNASDAQ: INM Suite 1445-885 West Georgia St. Vancouver, BC, Canada V6C 3E8 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Provides Update on BayMedica Commercial Business Vancouver, British Col
InMed Pharmaceuticals announced that the recently signed H.R. 5371 Act could significantly impact its subsidiary BayMedica’s commercial business. If implemented as currently drafted, aspects of BayMedica's cannabinoid inventory would become prohibited in November 2026. Despite this, InMed remains committed to its core pharmaceutical development programs, particularly in treating Alzheimer's and age-related macular degeneration. The company is exploring alternative supply chain options to ensure compliance with the new legislation.
Read more →INM▼ -11.5%on this news· ran to -27% by day 3
NASDAQ: INM 1445 - 885 West Georgia St. Vancouver, BC, Canada V6C 3E8 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Announces Successful Completion of Pharmacokinetic Studies in Large Animal
InMed Pharmaceuticals has successfully completed pharmacokinetic studies of its Alzheimer's disease candidate INM-901 in large animal models. The studies indicated robust bioavailability and supportive safety data, guiding the design for upcoming human clinical trials. The company has also progressed in chemistry, manufacturing, and controls development for INM-901, preparing for Investigational New Drug-enabling studies with the FDA. Overall, the results suggest a positive trajectory for InMed's Alzheimer's program.
Read more →INM▼ -5.5%on this news
NASDAQ: INM 1445 - 885 West Georgia St. Vancouver, BC, Canada V6C 3E8 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Pharmaceuticals Appoints Mr. John Bathery to Board of Directors Vancouver,
InMed Pharmaceuticals has appointed John Bathery to its Board of Directors, effective immediately. Bathery, who has over 30 years of experience in the pharmaceutical industry, will play a crucial role in advancing InMed's development programs, specifically in Alzheimer's disease and Age-Related Macular Degeneration. His expertise in corporate development and strategic partnerships is expected to greatly benefit the company's pipeline and potential collaborations. The announcement reflects InMed's strategic focus on growth and innovation.
Read more →INMNASDAQ: INM 1445 - 885 West Georgia St. Vancouver, BC, Canada V6C 3E8 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Pharmaceuticals Appoints Mr. Neil Klompas to it's Board of Directors Vancou
InMed Pharmaceuticals has appointed Mr. Neil Klompas to its Board of Directors, effective immediately. Klompas brings over 30 years of experience in healthcare and biotechnology, significantly contributing to Zymeworks' growth as a multi-billion-dollar company. He expressed enthusiasm for joining InMed, particularly regarding the promising data for INM-901, aimed at treating Alzheimer's disease. The board believes his expertise will be crucial as InMed progresses its development programs.
Read more →INM▼ -5.7%on this news
NASDAQ: INM 1445 - 885 West Georgia St. Vancouver, BC, Canada V6C 3E8 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Pharmaceuticals Reports Full Year Fiscal 2025 Financial Results and Provide
InMed Pharmaceuticals released its financial results for the fiscal year ending June 30, 2025, highlighting advancements in its drug development programs. The company's lead candidate, INM-901, shows promise in addressing Alzheimer's disease through multiple biological pathways. Additionally, their subsidiary BayMedica reported modest revenue growth. However, the company also noted a net loss that increased compared to the previous year, alongside expectations of rising research and development costs.
Read more →INMNASDAQ: INM 1445 - 885 West Georgia St. Vancouver, BC, Canada V6C 3E8 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed to Participate in the H.C. Wainwright 27th Annual Global Investment Confere
InMed Pharmaceuticals Inc. will participate in the H.C. Wainwright 27th Annual Global Investment Conference, which is scheduled for September 8-10, 2025, in New York. The management team will conduct one-on-one meetings with investors and present updates on the company's pipeline, particularly highlighting recent data from their Alzheimer's treatment program, INM-901. This presentation will also be available online for a limited time. InMed's focus remains on developing small molecule drug candidates targeting various medical conditions.
Read more →INMNASDAQ: INM 1445 - 885 West Georgia St. Vancouver, BC, Canada V6C 3E8 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed to Present INM-901 Data at Alzheimer's Association International Conference
InMed Pharmaceuticals Inc. (NASDAQ: INM) announced the presentation of new preclinical data for its INM-901 program at the Alzheimer's Association International Conference (AAIC) 2025. The presentation will focus on the therapeutic potential of INM-901 in mitigating Alzheimer's disease pathology, based on a long-term study using the 5xFAD mouse model. The research aims to validate earlier findings that suggest improvements in various behavioral and cognitive functions due to INM-901 treatment. The data will provide insights into a differentiated approach to Alzheimer's disease treatment.
Read more →INMNASDAQ: INM 1445 - 885 West Georgia St. Vancouver, BC, Canada V6C 3E8 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Pharmaceuticals Announces $5 Million Private Placement Priced At-the-Market
InMed Pharmaceuticals has announced a private placement agreement to raise $5 million through the issuance of common shares and short-term preferred investment options. The offering will close on or about June 25, 2025, and is expected to aid in the development of its pipeline of small molecule drug candidates, particularly for rare cannabinoids. However, it comes with risks, as there are no guarantees concerning the exercise of investment options and the securities remain unregistered. The company has also agreed to amend existing preferred investment options to lower their exercise price to align with this offering.
Read more →INMNASDAQ: INM 1445 - 885 West Georgia St. Vancouver, BC, Canada V6C 3E8 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Reports Third Quarter Fiscal 2025 Financial Results and Provides Business U
InMed Pharmaceuticals announced its financial results for the third quarter of fiscal 2025, reporting a net loss of $2.12 million, an increase from $1.72 million in the same period last year. The company is advancing its drug candidate INM-901 for Alzheimer's disease and has positive findings from preclinical studies of INM-089 for age-related macular degeneration. Despite stable revenues from BayMedica, the company faced challenges such as increased expenses and declining gross margins. InMed plans to seek additional funding to support its operational costs going forward.
Read more →INMRESIGNATION TO: lnMed Pharmaceuticals Inc. (the "Company") Attention: Andrew Hull, Chairman Dear Andrew, I hereby tender my resignation for approval by the Company's board of directors. Further, I hereby resign as a memb
Janet Grove has tendered her resignation to lnMed Pharmaceuticals Inc., effective immediately. Along with stepping down from her position as a board member, she also resigns from the Compensation Committee and Governance and Nomination Committee. This resignation may lead to concerns regarding the company's internal leadership stability.
Read more →INMNASDAQ: INM 1445 - 885 West Georgia St. Vancouver, BC, Canada V6C 3E8 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Reports Second Quarter Fiscal 2025 Financial Results and Provides Business
InMed Pharmaceuticals Inc. reported its financial results for Q2 of fiscal 2025, highlighting developments in its drug candidates INM-901 and INM-089. Notably, INM-901 showed promise in reducing neuroinflammatory markers linked to Alzheimer's disease. The company also experienced a rise in its net loss due to increased research and development expenses, despite the growth of its commercial operations marked by improved net income at BayMedica. InMed continues to monitor financials carefully as it advances its pipeline and product offerings.
Read more →INMNASDAQ: INM 1445 - 885 West Georgia St. Vancouver, BC, Canada V6C 3E8 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Announces INM-089 Intravitreal Formulation in the Treatment of Dry Age-Rela
InMed Pharmaceuticals has announced the selection of an intravitreal formulation for its drug candidate INM-089, aimed at treating dry age-related macular degeneration (AMD). The company has reported successful preclinical results, indicating that INM-089 can be effectively delivered to the targeted area of the eye. This development comes amid a significant unmet medical need for treatment options in the growing AMD patient population. The next steps include further preclinical studies and dose-ranging assessments.
Read more →INM▼ -20.8%on this news
NASDAQ: INM 1445 - 885 West Georgia St. Vancouver, BC, Canada V6C 3E8 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Pharmaceuticals Announces Granting of Patent for Novel Compounds Marks the
InMed Pharmaceuticals has announced the granting of an international Patent Cooperation Treaty (PCT) patent for proprietary small molecule compounds aimed at treating Alzheimer's disease and dry age-related macular degeneration. This patent, issued in Mexico, represents a significant step in strengthening InMed's intellectual property portfolio. The company remains focused on expanding its patent protection to safeguard innovative drug development and production methods. InMed plans to further file for patent issuance in multiple jurisdictions, underscoring its ongoing commitment to addressing high unmet medical needs.
Read more →INM▼ -16.2%on this news
NASDAQ: INM 1445 - 885 West Georgia St. Vancouver, BC, Canada V6C 3E8 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Announces Results of 2024 Annual General Meeting Vancouver, British Columbi
InMed Pharmaceuticals Inc. held its annual general meeting on December 18, 2024, where shareholders voted on several key matters. Four director nominees were elected, while Ms. Janet Grove's election was withheld, prompting her to offer her resignation. Marcum LLP was approved as the Company's auditors for the coming year. Approximately 39.83% of the Company's outstanding shares were represented at the meeting, indicating moderate shareholder engagement.
Read more →INMNASDAQ: INM 1445 - 885 West Georgia St. Vancouver, BC, Canada V6C 3E8 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Announces Publication of Study on Anti-Inflammation by Modulation of Endoca
InMed Pharmaceuticals has announced the publication of a peer-reviewed study that highlights the anti-inflammatory properties of cannabinol (CBN) in human keratinocytes. The research, conducted in collaboration with Dr. Mauro Maccarrone, demonstrates CBN's modulation of the endocannabinoid system and its potential therapeutic applications in skin diseases. This study supports InMed's focus on inflammation-related conditions and enhances understanding of targets related to the endocannabinoid system.
Read more →INM▲ +9.3%on this newsshared move
NASDAQ: INM 1445 - 885 West Georgia St. Vancouver, BC, Canada V6C 3E8 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Reports First Quarter Fiscal 2025 Financial Results and Provides Business U
InMed Pharmaceuticals reported its financial results for the first quarter of fiscal 2025, revealing notable developments in its drug candidate INM-901 for Alzheimer's disease. The company highlighted significant progress in preclinical studies, which showed promising behavioral data and multiple mechanisms of action. Additionally, BayMedica's commercial operations contributed to a 40% increase in revenue year-over-year, amounting to $1.3 million. However, InMed also reported a net loss of $1.68 million and a decline in cash reserves, signaling the need for careful financial management as it progresses into further studies.
Read more →INMNASDAQ: INM Suite 1445-885 West Georgia St. Vancouver, BC, Canada V6C 3E8 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Announces Share Consolidation to Satisfy Nasdaq Listing Rules Vancouver
InMed Pharmaceuticals Inc. has announced a share consolidation plan whereby each shareholder will receive one post-consolidation share for every twenty pre-consolidation shares. This consolidation is aimed at regaining compliance with Nasdaq's continued listing requirements and is expected to take effect on November 14, 2024. Following this consolidation, the number of outstanding shares will be reduced from approximately 14.4 million to about 718,078 shares, and trading will begin with a new CUSIP and ISIN number. Registered shareholders will receive instructions regarding their shares in the mail.
Read more →INM▼ -7.4%on this newsshared move
NASDAQ: INM 1445 - 885 West Georgia St. Vancouver, BC, Canada V6C 3E8 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Pharmaceuticals Announces Decision by Nasdaq Hearings Panel to Grant Except
InMed Pharmaceuticals has been granted an extension by the Nasdaq Hearings Panel to implement a share consolidation to comply with listing rules. The company did not meet the minimum bid price of $1.00 per share by September 2024, prompting a hearing. The Panel's decision supports InMed's ongoing efforts to regain compliance by December 2, 2024, although risks remain regarding their ability to meet these requirements.
Read more →INM▲ +6.6%on this news· ran to -20% by day 3
NASDAQ: INM 1445 - 885 West Georgia St. Vancouver, BC, Canada V6C 3E8 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Pharmaceuticals Files Additional Patent Application for INM-901 in the Trea
InMed Pharmaceuticals has filed an additional international patent application for INM-901, aimed at treating neurodegenerative conditions like Alzheimer's disease. This application, which falls under the Patent Cooperation Treaty, outlines the drug's pharmaceutical composition and various methods of use. The company highlights significant progress with INM-901 and intends to advance the program towards human clinical trials, promising to share long-term in vivo data soon. This development enhances InMed's growing patent portfolio, which already includes multiple families focused on drug formulation and manufacturing technologies.
Read more →INMNASDAQ: INM 1445 - 885 West Georgia St. Vancouver, BC, Canada V6C 3E8 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed to Participate in Fierce Biotech Webinar on Neuroinflammation in Alzheimer'
InMed Pharmaceuticals Inc. announced its participation in the "Alzheimer's Outlook - Neuroinflammation, the Next Step" webinar scheduled for November 12, 2024. The company's Senior VP, Dr. Eric Hsu, will join a panel of experts to discuss recent trends and advancements in Alzheimer's disease research, particularly focused on neuroinflammation. InMed is advancing its drug candidate INM-901, which has shown promise in preclinical studies for the treatment of Alzheimer's disease. This involvement highlights InMed's commitment to addressing high unmet medical needs in neurodegenerative diseases.
Read more →INM▲ +10%on this newsshared move
NASDAQ: INM 1445 - 885 West Georgia St. Vancouver, BC, Canada V6C 3E8 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Appoints Dr. Barry Greenberg, Johns Hopkins University School of Medicine,
InMed Pharmaceuticals has appointed Dr. Barry Greenberg to its Scientific Advisory Board. Dr. Greenberg, a prominent figure in Alzheimer's research and the Director at Johns Hopkins University's Alzheimer Disease Translational Center, brings over four decades of expertise. His involvement is expected to provide valuable guidance as the company advances its INM-901 drug candidate toward clinical trials for Alzheimer's disease, with promising preclinical outcomes reported.
Read more →INMNASDAQ: INM InMed Pharmaceuticals Reports Full Year Fiscal 2024 Financial Results and Provides Business Update Advances INM-901 program targeting several biological pathways associated with Alzheimer's disease Further de
InMed Pharmaceuticals announced its financial results for the fiscal year ending June 30, 2024, highlighting advancements in its drug development pipeline, particularly the INM-901 program targeting Alzheimer's disease. The company reported a slight net loss reduction, reaching $7.7 million, while BayMedica's revenue grew by 11% to $4.6 million. Additionally, there has been positive pharmacological data for the INM-089 drug candidate for dry AMD, and three new U.S. patents have been issued. Despite a decrease in cash reserves and expectations for increased R&D expenses, the overall focus on innovative therapies continues to position InMed favorably in the biopharma landscape.
Read more →INMNASDAQ: INM Suite 1445-885 W. Georgia St. Vancouver, BC, Canada V6C 3E8 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Receives Nasdaq Delisting Notice, and Confirms it has Filed an Appeal and
InMed Pharmaceuticals Inc. has received a delisting notice from Nasdaq after failing to meet the minimum bid price requirement. The company has filed an appeal and obtained a hearing to present its compliance plan. While the appeal has halted immediate delisting actions, there is no assurance of a favorable outcome from the Listing Qualifications Panel. If the appeal is not granted, the company might face stringent criteria or delisting.
Read more →INMNASDAQ: INM 1445 - 885 West Georgia St. Vancouver, BC, Canada V6C 3E8 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Pharmaceuticals Strengthens Patent Portfolio with Issuance of Three U.S. Pa
InMed Pharmaceuticals announced the issuance of three U.S. patents, enhancing its patent portfolio. The patents cover a topical cannabinoid treatment for epidermolysis bullosa, biosynthesis manufacturing processes, and an ocular drug delivery formulation. The INM-755 candidate, which has completed a Phase 2 clinical trial, is among the patented products aimed at addressing diseases with high unmet medical needs. The company continues to pursue additional patents related to its drug candidates for Alzheimer's and macular degeneration.
Read more →INM▲ +191.4%on this newsshared move
NASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Pharmaceuticals Demonstrates INM-901 as an Oral Formulation Targeting Alz
InMed Pharmaceuticals has confirmed its proprietary compound INM-901 as an oral formulation aimed at treating Alzheimer's disease. Recent preclinical studies show that INM-901 can achieve therapeutic levels in the brain when administered orally, similar to intraperitoneal delivery. This breakthrough could enhance the accessibility and cost-effectiveness of treatments for Alzheimer's, addressing some of the challenges faced by current therapies that rely on large molecule injections. The company plans to conduct additional studies to support an Investigational New Drug submission for INM-901.
Read more →INM▼ -17.6%on this news· ran to -37% by day 3
NASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Pharmaceuticals Announces Favorable Behavioral Outcomes with INM-901 in L
InMed Pharmaceuticals has announced favorable results from a long-term preclinical Alzheimer's Disease study involving its drug candidate INM-901. This study confirmed previous positive outcomes from an earlier short-term pilot study, showing significant behavioral improvements in treated groups compared to placebo. The findings suggest that INM-901 effectively targets biological pathways associated with Alzheimer's. Further analyses and development activities are planned to support potential IND submission, highlighting the company's commitment to addressing unmet medical needs in Alzheimer's treatment.
Read more →INMNASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed to Present at the Emerging Growth Conference Vancouver, BC
InMed Pharmaceuticals Inc. has announced its participation at the Emerging Growth Conference scheduled for June 12-13, 2024. CEO Eric A. Adams will provide a corporate overview, followed by a Q&A session. The company is focused on developing proprietary small molecule drug candidates aimed at treating Alzheimer's and other conditions, highlighting its ongoing advancements within the pharmaceutical sector. Attendees will have the opportunity to view the presentation live or access an archived version later.
Read more →INMNASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Pharmaceuticals Reports Third Quarter Fiscal 2024 Financial Results and P
InMed Pharmaceuticals reported its financial results for the third quarter of fiscal 2024, showcasing growth in its commercial business and ongoing advancements in its drug development pipeline, particularly for Alzheimer's disease and dry AMD. The company indicated stable revenues from its BayMedica unit but acknowledged a net loss that has increased over the same period last year. Financial forecasts suggest sufficient cash to meet operational needs into late 2024, although revenue may fluctuate. Notably, the addition of a new expert to its advisory board strengthens its commitment to advancing its research programs.
Read more →INMNASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Appoints Dr. David G. Morgan, PhD, a Leading Alzheimer's Expert, to the C
InMed Pharmaceuticals has appointed Dr. David G. Morgan, a leading figure in Alzheimer's research, to its Scientific Advisory Board. This appointment is expected to enhance the development of InMed's INM-901 program aimed at treating Alzheimer's disease. Dr. Morgan, known for his work on immunotherapy and gene therapy, brings substantial experience that could contribute significantly to the program's success. The company expresses confidence that his expertise will guide them in the next stages of the INM-901 development.
Read more →INMNASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Provides Update on INM-089 in the Treatment of Dry Age-Related Macular De
InMed Pharmaceuticals has announced additional preclinical data regarding INM-089, demonstrating promising pharmacological effects in treating dry Age-Related Macular Degeneration (AMD). The recent data suggests that INM-089 could be more effective than existing treatments and offers potential benefits against geographic atrophy, a severe form of dry AMD. The company is currently advancing its development activities by engaging a Contract Development and Manufacturing Organization (CDMO) for scaling up production. Further studies are planned to explore the drug's mechanisms of action and pharmacokinetics.
Read more →INMNASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed's INM-901 Demonstrates Favorable Pharmacological and Behavioral Effects i
InMed Pharmaceuticals announced promising preclinical data for INM-901, indicating its potential as a treatment for Alzheimer's disease. The research shows the drug's favorable pharmacological effects and mechanisms of action targeting cannabinoid receptors and neuroinflammation. InMed plans to advance its Alzheimer's development program with ongoing studies scheduled for completion in the third quarter of 2024. However, the results emphasize the necessity for further research to confirm INM-901’s efficacy in clinical settings.
Read more →INMNASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Granted 180-Day Extension to Achieve Nasdaq Minimum Bid Compliance Vancou
InMed Pharmaceuticals has received a 180-day extension from Nasdaq to regain compliance with its minimum bid price requirement, previously set at $1.00. The extension allows the company until September 16, 2024, to restore compliance, although it must maintain the bid price for at least 10 consecutive business days to meet the requirement. Despite this positive news, the company's inability to meet the bid price in the past raises concerns about its future compliance status. InMed continues to trade under the symbol 'INM' but must consider all options, including a potential reverse stock split, to enhance its share price.
Read more →INMNASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Reports Second Fiscal Quarter 2024 Financial Results and Provides Busines
InMed Pharmaceuticals reported its financial results for Q2 of fiscal 2024, highlighting a 164% revenue increase for its subsidiary, BayMedica. The company's cash reserves exceed $9.5 million, enabling the pursuit of key developments, including INM-901 for Alzheimer's disease and INM-089 for age-related macular degeneration. Despite these positive developments, InMed continues to face financial losses and uncertain revenue streams as it navigates the rare cannabinoids market.
Read more →INMNASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Pharmaceuticals Strengthens Executive Leadership Team with Appointment of
InMed Pharmaceuticals announced the appointment of Ms. Netta Jagpal as Chief Financial Officer and Corporate Secretary, effective February 20, 2024. Ms. Jagpal has over 20 years of experience in financial roles within the biotech sector and has served in leadership positions at companies such as D-Wave Systems and Zymeworks. The transition will also see Mr. Jonathan Tegge stepping down as Interim CFO. InMed continues to focus on the development and commercialization of cannabinoid therapeutics.
Read more →INMNASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed to Discuss Its Pharmaceutical Pipeline and 2024 Strategic Priorities in F
InMed Pharmaceuticals Inc. (NASDAQ: INM) is set to discuss its pharmaceutical pipeline and 2024 strategic priorities during a Fireside Chat with Water Tower Research on January 25, 2024. The event will provide insights into the company's innovative development of rare cannabinoid therapeutics and its engagement strategies with investors. Interested parties can register to attend, and a replay will be available post-event. InMed continues to emphasize its role in the cannabinoid health sector alongside its subsidiary, BayMedica.
Read more →INMNASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Pharmaceuticals Provides Business Update and Milestones for 2024 Advancin
InMed Pharmaceuticals has provided an update on its strategic priorities and achievements from 2023, highlighting advancements in its drug development pipeline for Alzheimer's disease and Age-related Macular Degeneration. The company is optimistic about the potential of INM-901 in Alzheimer's treatment and signals plans to initiate IND-enabling studies for INM-089. Additionally, BayMedica, InMed's subsidiary, continues to experience growth in the health and wellness market, driven by demand for cannabinoid ingredients. Preparations for further studies are underway, suggesting a positive outlook for InMed's future.
Read more →INMNASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Announces Results of 2023 Annual General Meeting Vancouver, BC
InMed Pharmaceuticals Inc. held its annual general meeting on December 19, 2023, where shareholders approved all proposed matters. A total of 1,292,647 shares were represented, constituting about 38.84% of the total shares. The meeting featured the election of director nominees who will hold office until the next annual meeting. InMed's leadership in the cannabinoid sector and its commitment to developing innovative treatments were highlighted.
Read more →INM▲ +21.7%on this news
NASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Expands its Pharmaceutical Pipeline with INM-089 Targeting the Treatment
InMed Pharmaceuticals has announced the launch of INM-089, a cannabinol (CBN) analog aimed at treating Age-related Macular Degeneration (AMD). This development follows promising study results indicating that INM-089 preserves retinal function in AMD models. The company emphasizes the potential of this treatment to address the unmet medical needs in neuroprotective therapies for AMD. Additionally, INM-089 is part of a broader ocular pipeline that includes other therapeutic indications.
Read more →INMNASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Reports First Quarter Fiscal 2024 Financial Results and Provides Business
InMed Pharmaceuticals Inc. has reported its financial results for the first quarter of fiscal year 2024, highlighting advancements in their pharmaceutical programs and steady growth in their commercial operations. The company recently launched the INM-901 preclinical program aimed at treating Alzheimer's disease, which has shown promising results in early studies. Additionally, InMed's subsidiary, BayMedica, experienced significant revenue growth of 181% year-over-year but faced a quarter-over-quarter revenue decrease. The company remains optimistic about its financial health with recent financing enhancing its balance sheet and extending its cash runway into 2024.
Read more →INMNASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Announces Presentation of INM-755 Phase 2 Clinical Study Results at 12th
InMed Pharmaceuticals announced that the results of its Phase 2 clinical study for the CBN cream, INM-755, will be presented at the 12th World Congress on Itch. The study evaluates the cream's safety and preliminary efficacy in treating epidermolysis bullosa (EB) symptoms. Data indicated a positive outcome with enhanced anti-itch activity compared to control cream. The presentation is set for November 7, 2023, showcasing the company's ongoing efforts in cannabinoid research and development.
Read more →INM▲ +70.5%on this news
NASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Pharmaceuticals Announces $5.2 Million Private Placement and Preferred In
InMed Pharmaceuticals announced a $5.2 million private placement involving 3,012,049 common shares and preferred investment options. The company intends to utilize the proceeds to support the development of pharmaceutical candidates and commercial sales through its subsidiary. The offerings are scheduled to close on or about October 26, 2023, pending customary closing conditions. This financing will assist in advancing InMed's mission focused on rare cannabinoids and meeting high unmet medical needs.
Read more →INMNASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Pharmaceuticals Reports Full Year Fiscal 2023 Financial Results and Provi
InMed Pharmaceuticals reported financial results for the fiscal year ending June 30, 2023, highlighting a significant increase in revenue for its subsidiary, BayMedica. The company indicated growth in the rare cannabinoids market and positive developments in its clinical trials, particularly with its INM-755 product for chronic itch. However, some trial outcomes were statistically insignificant, and future revenue growth may be inconsistent due to market fluctuations. The company is continuing to explore strategic partnerships for further pharmaceutical advancements.
Read more →INMNASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed to Present at H.C. Wainwright 25th Annual Global Investment Conference Va
InMed Pharmaceuticals Inc. has announced that its CEO, Eric A. Adams, will present an overview of the company at the H.C. Wainwright 25th Annual Global Investment Conference from September 11-13, 2023, in New York City. The presentation will be available via webcast on September 11, 2023, and will remain accessible for 90 days. Additionally, the management team is arranging one-on-one meetings with registered investors during the conference to discuss the company's developments in cannabinoid pharmaceuticals.
Read more →INMNASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed to Participate in Fireside Chat with Water Tower Research on
InMed Pharmaceuticals will participate in a Fireside Chat hosted by Water Tower Research on July 25, 2023, at 2:00 PM ET. Jerry Griffin, the VP of Sales and Marketing for InMed's subsidiary BayMedica, will address topics related to rare cannabinoids in the Health and Wellness market. The event is intended for all investors and will provide valuable insights into the company's operations and developments. Interested participants can register for the event and access replays afterward.
Read more →INM▲ +5.3%on this news· ran to +24% by day 3shared move
NASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Provides Update on BayMedica Rare Cannabinoid Business $2.3M revenues (un
InMed Pharmaceuticals Inc. provided a commercial update regarding its subsidiary, BayMedica, reporting growth in revenue exceeding $2.3M for the third consecutive quarter. BayMedica focuses on the supply of bioidentical rare cannabinoids to the Health and Wellness market, with efforts made to optimize the supply chain and increase production capacity. While InMed anticipates an overall net loss for the fiscal year, management remains optimistic about BayMedica's potential for profitability as demand for rare cannabinoids continues to rise.
Read more →INM▼ -13.6%on this news· ran to -24% by day 3
NASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Pharmaceuticals Inc. Announces Results from a Phase 2 Clinical Trial in E
InMed Pharmaceuticals Inc. announced positive results from its Phase 2 clinical trial for INM-755 CBN cream, aimed at treating symptoms related to Epidermolysis Bullosa (EB). The trial enrolled 19 patients, revealing that 66.7% experienced a clinically meaningful improvement in chronic non-wound itch. Although the statistical significance was affected by the control cream's efficacy, the product was well tolerated, showing no serious adverse events. The company plans to pursue further research and partnerships for continued development of INM-755.
Read more →INMNASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed's Neurodegenerative Disease Study Presented at Canadian Neuroscience Meet
InMed Pharmaceuticals presented research results at the Canadian Neuroscience Meeting, highlighting the potential of a specific rare cannabinoid, pCBx, in combating neurodegenerative diseases. The study demonstrated that pCBx reduces amyloid toxicity and enhances neuronal growth, suggesting its role in therapeutic interventions for Alzheimer's and similar conditions. Furthermore, two cannabinoid analogs from InMed's 900 Series program have shown significant promise, leading to further in vivo studies. The company has also filed an international patent application related to these findings.
Read more →INMNASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed to Participate in Upcoming Virtual Investor Events Vancouver, BC
InMed Pharmaceuticals Inc. has announced its participation in upcoming virtual investor events, emphasizing the rising demand for rare cannabinoids. CEO Eric A. Adams and VP Jerry Griffin will co-host a presentation that includes a corporate overview and Q&A session. These efforts aim to solidify InMed's position as a leader in cannabinoid research, development, and commercialization. Additionally, recordings of the presentations will be provided for those unable to attend live.
Read more →INMNASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Pharmaceuticals Reports Third Quarter Fiscal 2023 Financial Results and P
InMed Pharmaceuticals reported its third quarter financial results for fiscal 2023, highlighting significant milestones including the completion of enrollment in a Phase 2 clinical trial for epidermolysis bullosa. The company's subsidiary, BayMedica, achieved over $1 million in quarterly revenues, reflecting a 120% increase compared to the previous quarter, driven by rising demand in the Health and Wellness sector. Despite reporting a net loss of $7.6 million for the nine months ended March 31, 2023, InMed remains optimistic due to strong growth in cannabinoid research and development.
Read more →INM▼ -9.4%on this news
NASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Announces Conclusion of Patient Enrollment in Phase 2 Clinical Trial Inve
InMed Pharmaceuticals has announced the completion of patient enrollment for its Phase 2 clinical trial of INM-755 cannabinol cream, aimed at treating epidermolysis bullosa. The study enrolled 19 patients across all four subtypes of the disease to evaluate the safety and preliminary efficacy of the treatment. Results from the trial are expected in early Q3 2023, marking a critical step in the research of cannabinoids as therapeutic options for rare diseases.
Read more →INM▲ +7.6%on this news
NASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Announces Publication of Peer-Reviewed Study Showing the Anti-Inflammator
InMed Pharmaceuticals announced the publication of a peer-reviewed study highlighting the anti-inflammatory potential of rare cannabinoids for treating skin conditions. The study, published in the International Journal of Molecular Sciences, details the biochemical mechanisms through which cannabinoids like THCV and CBGA exhibit inflammation-blocking properties. This follows InMed's ongoing commitment to exploring the therapeutic applications of rare cannabinoids, enhancing understanding of their pharmacological properties. The research opens new avenues for potential treatments of conditions such as atopic dermatitis and psoriasis.
Read more →INM▲ +9.8%on this news
NASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed to Participate in Upcoming Investor Events Vancouver, BC
InMed Pharmaceuticals announced that its executive team will participate in upcoming virtual investor events throughout March 2023. CEO Eric A. Adams will present a corporate overview and engage in Q&A sessions at both the Emerging Growth Conference and Virtual Investor Conferences. The company has also changed its registrar and transfer agent, replacing Computershare Trust Company with Odyssey Trust Company, and entered a consulting agreement with LFG Equities Corp. for strategic advice and media services.
Read more →INMNASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Reports Second Quarter Fiscal 2023 Financial Results and Provides Busines
InMed Pharmaceuticals Inc. announced its financial results for the second quarter of fiscal 2023, reporting a net loss of $5.6 million. The company is making substantial progress in its clinical trials, particularly with the INM-900 series aimed at treating neurodegenerative diseases and nearing completion of its Phase 2 trial for Epidermolysis Bullosa. Notably, InMed has experienced increased revenues from its BayMedica segment, reflecting a strategic effort in cannabinoid production. The company maintains a cash position of over $11 million, indicating potential for continued investments in development opportunities.
Read more →INM▲ +36.1%on this news
NASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Provides Business Update and Milestones for 2023 Complete Phase 2 clinica
InMed Pharmaceuticals Inc. provided a business update outlining key accomplishments from 2022 and future milestones for 2023. The company has made significant progress in its clinical trials, particularly for INM-755, which is being tested for Epidermolysis Bullosa. InMed is also advancing its neurodegenerative disease program and exploring human trials for its INM-088 treatment for glaucoma. Despite facing some challenges in market demand and funding, they expect to continue achieving material milestones that could enhance shareholder value.
Read more →INM▼ -7%on this news
NASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Announces Results of 2022 Annual General Meeting Vancouver, BC
InMed Announces Results of 2022 Annual General Vancouver, BC - December 15, 2022 - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (Nasdaq: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today co
Read more →INMNASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Announces Appointment of Interim Chief Financial Officer and Change of Au
InMed Announces Appointment of Interim Chief Financial Officer and Change of Auditor Vancouver, BC - December 12, 2022 - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (Nasdaq: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabi
Read more →INM▼ -28.1%on this news
NASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Pharmaceuticals Announces $6 Million Private Placement Priced at a Premiu
InMed Pharmaceuticals Announces $6 Million Private Placement Priced at a Premium to Market November 18, 2022 - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (Nasdaq: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids,
Read more →INM▲ +36.3%on this newsshared move
NASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Pharmaceuticals Advances Neurodegenerative Disease Program with Natural S
Pharmaceuticals Advances Neurodegenerative Disease Program with Natural Sciences and Engineering Research Council of Canada ("NSERC") Alliance Grant Funding Vancouver, BC - November 16, 2022 - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (Nasdaq: INM), a leader in the
Read more →INMNASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Pharmaceuticals Reports First Quarter Fiscal 2023 Financial Results and P
InMed Pharmaceuticals Reports First Quarter Fiscal 2023 Financial Results and Provides Business Update Vancouver, BC - November 11, 2022 - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (Nasdaq: INM), a leader in the pharmaceutical research, development and manufacturi
Read more →INM▲ +9.1%on this news
NASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Pharmaceuticals Supports Epidermolysis Bullosa Awareness Week Vancouver,
InMed Pharmaceuticals Supports Epidermolysis Bullosa Awareness Week October 26, 2022 - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (Nasdaq: INM), a leader in the research, development and manufacturing of rare cannabinoids, announces it is supporting initiatives to r
Read more →INMBurrard St, 3rd Floor Vancouver BC, V6C 3B9 www.computershare.com
Subject: INMED PHARMACEUTICALS INC. We advise of the following with respect to the upcoming Meeting of Security Holders for the subject Issuer: Meeting Type : Annual General Meeting Record Date for Notice of Meeting : October 24, 2022 Record Date for Voting (if applicable) : Oc
Read more →INM▼ -19.5%on this news
NASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Pharmaceuticals Reports Full Year Fiscal 2022 Financial Results and Provi
Pharmaceuticals Reports Full Year Fiscal 2022 Financial Results and Provides Business Update BC - September 23, 2022 - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (Nasdaq: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoi
Read more →INMNASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Announces Share Consolidation to Meet Nasdaq Listing Criteria Vancouver,
InMed Announces Share Consolidation to Meet Nasdaq Listing Criteria Vancouver, BC - August 23, 2022 - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (Nasdaq: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today an
Read more →INMNASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Announces Changes to its Board of Directors Vancouver, BC
InMed Announces Changes to its Board of Directors August 9, 2022 - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (Nasdaq: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, is pleased to announce the appointment of Nic
Read more →INMNASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Announces Update on Phase 2 Clinical Trial Investigating INM-755 Cannabin
Announces Update on Phase 2 Clinical Trial Investigating INM-755 Cannabinol Cream for Epidermolysis Bullosa BC - July 25, 2022 - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (Nasdaq: INM), a leader in the research, development, manufacturing and commercialization of ra
Read more →INMInMed Announces Appointment of Chief Operating Officer
InMed Announces Appointment of Chief Operating Officer VANCOUVER, British Columbia, July 18, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. ("InMed" or the "Company") (Nasdaq: INM), a leader in the research, development, manufacturing and commercialization of rare cannabi
Read more →INMNASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Announces Publication of Peer-Reviewed Study Highlighting Potential Role
InMed Announces Publication of Peer-Reviewed Study Highlighting Potential Role of Rare Cannabinoids THCV, CBC and others on Skin Conditions June 14, 2022 - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (Nasdaq: INM), a leader in the research, development, manufacturin
Read more →INMNASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Launches THCV, Expanding its Portfolio of Rare Cannabinoids for the Healt
Launches THCV, Expanding its Portfolio of Rare Cannabinoids for the Health and Wellness Sector BC - June 09, 2022 - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (Nasdaq: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoi
Read more →INMNASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Pharmaceuticals Announces Closing of $5 Million Registered Direct and Pri
InMed Pharmaceuticals Announces Closing of $5 Million Registered Direct and Private Placement Offerings Priced At-The-Market Under Nasdaq Rules June 06, 2022 - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (Nasdaq: INM), a leader in the research, development, manufactu
Read more →INMNASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Pharmaceuticals Announces $5 Million Registered Direct and Private Placem
InMed Pharmaceuticals Announces $5 Million Registered Direct and Private Placement Offerings Priced At-The-Market Under Nasdaq Rules June 02, 2022 - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (Nasdaq: INM), a leader in the research, development, manufacturing and
Read more →INMNASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Pharmaceuticals Reports Third Quarter Fiscal 2022 Financial Results and P
InMed Pharmaceuticals Reports Third Quarter Fiscal 2022 Financial Results and Provides Business Update Vancouver, BC and South San Francisco, CA - May 13, 2022 - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (Nasdaq: INM), a leader in the research, development, manufa
Read more →INMNASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed to Supply Rare Cannabinoids to Radicle Science's "Radicle Energy Study" t
to Supply Rare Cannabinoids to Radicle Science's "Radicle Energy Study" to Assess the Health Effects of THCV Vancouver, BC and South San Francisco, CA - May 05, 2022 - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (Nasdaq: INM), a leader in the research, development,
Read more →INMNASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Expands Patent Portfolio with Novel Cannabinoid Analogs and Advances Coll
InMed Expands Patent Portfolio with Novel Cannabinoid Advances Collaboration Agreement with Leading Cannabinoid Research Expert Vancouver, BC and South San Francisco, CA - April 28, 2022 - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (Nasdaq: INM), a leader in the re
Read more →INMNASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Commercializes Cannabidivarin (CBDV), Expanding its Rare Cannabinoid Port
Commercializes Cannabidivarin (CBDV), Expanding its Rare Cannabinoid Portfolio for the Health and Wellness Sector BC and South San Francisco, CA - April 21, 2022 - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (Nasdaq: INM), a leader in the research, development, manufa
Read more →INMNASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed to Participate in Upcoming Investor Conferences in April and May 2022 Van
to Participate in Upcoming Investor Conferences in April and May 2022 BC - April 19, 2022 - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (Nasdaq: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, announces that the C
Read more →INMNASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Announces Management Changes Vancouver, BC
InMed Announces Management Vancouver, BC - March 17, 2022 - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (Nasdaq: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today announces that its Chief Financial Officer, M
Read more →INMNASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed to Present at the 34th Annual Roth Conference Vancouver, BC
to Present at the 34th Annual Roth Conference BC - March 8, 2022 - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (Nasdaq: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today announces that Eric A. Adams, InMed's
Read more →INMNASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Pharmaceuticals Strengthens its Commercial Leadership Team with the Appoi
InMed Pharmaceuticals Strengthens its Commercial with the Appointment of Vice President of Sales and Marketing for Vancouver, BC - February 15, 2022 - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (Nasdaq: INM), a leader in the research, development, manufacturing and
Read more →INMNASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Pharmaceuticals to Report Second Quarter Fiscal 2022 Financial Results an
InMed Pharmaceuticals to Report Second Quarter Fiscal 2022 Financial Results and Business Update on February 15, 2022 Vancouver, BC - February 10, 2022 - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (Nasdaq: INM), a leader in the research, development, manufacturing
Read more →INMNASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Launches Cannabicitran (CBT), Expanding its Rare Cannabinoid Portfolio
InMed Launches Cannabicitran (CBT), Expanding its Rare Cannabinoid Portfolio for the Health and Wellness Sector Vancouver, BC - January 19, 2022 - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (Nasdaq: INM), a leader in the research, development, manufacturing and com
Read more →INMNASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Issues Annual Letter to Shareholders Highlighting Key Accomplishments fro
Issues Annual Letter to Shareholders Highlighting Key Accomplishments from 2021 and Providing 2022 Outlook BC - January 5, 2022 - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (Nasdaq: INM), a leader in the development, manufacturing and commercialization of rare canna
Read more →INMBayMedica, Inc. AUDITED FINANCIAL STATEMENTS YEAR ENDED DECEMBER 31, 2020 AND INDEPENDENT AUDITORS ' REPORT BayMedica, Inc. (Expressed in U.S. Dollars) For the Year Ended
AUDITED FINANCIAL STATEMENTS YEAR ENDED DECEMBER 31, 2020 INDEPENDENT AUDITORS' REPORT the Year Ended December 31, 2020 Independent Auditor's Report 1 Balance Sheet 2 Statement of Operations 3 Statement of Shareholders' Deficit 4 Statement of Cash Flows 5 Notes to the Financi
Read more →INMNASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Pharmaceuticals to Participate in Cowen's 4th Annual Cannabis Conference
InMed Pharmaceuticals to Participate in Cowen's November 23, 2021 - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (Nasdaq: INM), a leader in the development, manufacturing and commercialization of rare cannabinoids, today announced that InMed's management team is schedu
Read more →INMNASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Pharmaceuticals Reports First Quarter Fiscal 2022 Financial Results and P
InMed Pharmaceuticals Reports First Quarter Fiscal 2022 Financial Results and Provides Business Update Vancouver, BC - November 10, 2021 - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (Nasdaq: INM), a leader in the development, manufacturing and commercialization of
Read more →INMNASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Pharmaceuticals Files PCT Patent Application for Treating Neurodegenerati
InMed Pharmaceuticals Files PCT Patent Application for Treating Neurodegenerative Disease Using a Rare Cannabinoid Vancouver, BC - November 3, 2021 - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (Nasdaq: INM), a leader in the manufacturing, development and commercial
Read more →INMBurrard St, 3rd Floor Vancouver Date
510 Burrard St, 3rd Floor Vancouver Date: October 27, 2021 BC, V6C 3B9 www.computershare.com To: All Canadian Securities Regulatory Authorities Subject: INMED PHARMACEUTICALS INC. We advise of the following with respect to the upcoming Meeting of Security Holders for the su
Read more →INMNASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Pharmaceuticals Completes Acquisition of BayMedica Creating a Market Lead
InMed Pharmaceuticals Completes Acquisition of BayMedica Creating a Market Leader in the Manufacturing of Rare Cannabinoids Vancouver, BC and South San Francisco, CA - October 13, 2021 - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (Nasdaq: INM), a leader in the manu
Read more →INMNASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Pharmaceuticals Announces Commencement of Phase 2 Clinical Trial Investig
Pharmaceuticals Announces Commencement of Phase 2 Clinical Trial Investigating Cannabinol (CBN), a Rare Cannabinoid, in the Treatment of Epidermolysis Bullosa BC - September 30, 2021 - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (Nasdaq: INM), a leader in the manufa
Read more →INMNASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Pharmaceuticals Reports Full Year Fiscal 2021 Financial Results and Provi
Pharmaceuticals Reports Full Year Fiscal 2021 Financial Results and Provides Business Update BC - September 24, 2021 - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (Nasdaq: INM), a leader in the manufacturing and clinical development of rare cannabinoids, today reporte
Read more →INMNASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Pharmaceuticals and BayMedica Participating in Tribe Public's Webinar "Ac
InMed Pharmaceuticals and BayMedica Participating in Tribe Public's Webinar "Accelerating The Commercialization of Registration for the September 21, 2021 event Vancouver, BC - September 17, 2021 - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (Nasdaq: INM), a leader
Read more →INMNASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Pharmaceuticals Signs Definitive Agreement to Acquire BayMedica, a Leadin
InMed Pharmaceuticals Signs Definitive Agreement to Acquire BayMedica, a Leading Commercial Manufacturer of Rare Cannabinoids Vancouver, BC - September 13, 2021 - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (Nasdaq: INM), a leader in the manufacturing and clinical d
Read more →INMNASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Pharmaceuticals to Present at the H.C. Wainwright 23 rd Annual Global Inv
InMed Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference Vancouver, BC - September 9, 2021 - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (Nasdaq: INM), a leader in the manufacturing and clinical development of rare cannabinoid
Read more →INMInMed Pharmaceuticals to Webcast Live at VirtualInvestorConferences.com September 8 th InMed Pharmaceuticals invites individual and institutional investors, as well as advisors and analysts, to attend real-time, interact
InMed Pharmaceuticals to Webcast Live at VirtualInvestorConferences.com September 8th InMed Pharmaceuticals invites individual and institutional investors, as well as advisors and analysts, to attend real-time, interactive presentations on VirtualInvestorConferences.com Vanco
Read more →INMNASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Pharmaceuticals to Present at the H.C. Wainwright Ophthalmology Virtual C
InMed Pharmaceuticals to Present at the H.C. Wainwright Ophthalmology Virtual Conference Vancouver, BC - August 12, 2021 - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (Nasdaq: INM), a clinical-stage company developing cannabinoid-based pharmaceutical drug candidates
Read more →INMNASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Pharmaceuticals Announces Closing of US$12 Million Private Placement Pric
InMed Pharmaceuticals Announces Closing of US$12 Million Private Placement Priced At-the-Market under Vancouver, BC - July 2, 2021 - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (Nasdaq: INM), a clinical-stage company developing cannabinoid-based pharmaceutical drug
Read more →INMNASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Pharmaceuticals Announces $12 Million Private Placement Priced At-the-Mar
InMed Pharmaceuticals Announces $12 Million Priced At-the-Market under Nasdaq Rules Vancouver, BC - June 29, 2021 - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (Nasdaq: INM), a clinical-stage company developing cannabinoid-based pharmaceutical drug candidates as wel
Read more →INM, DATED JUNE 29, 2021 E xhibit 99.1 NASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Pharmaceuticals Signs Non
InMed Pharmaceuticals Signs Non-binding Letter of Intent to Acquire BayMedica, a Commercial Manufacturer of Rare Cannabinoids Vancouver, BC - June 29, 2021 - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (Nasdaq: INM), a clinical-stage company developing cannabinoid-
Read more →INMInMed Pharmaceuticals to Webcast Live at Life Sciences Investor Forum June 24 th InMed invites individual and institutional investors, as well as advisors and analysts, to attend a real-time, interactive presentation on
InMed Pharmaceuticals to Webcast Live at Life Sciences Investor InMed invites individual and institutional investors, as well as advisors and analysts, to attend a real-time, interactive presentation on LifeSciencesInvestorForum.com Vancouver, BC - June 22, 2021 /GLOBE NEWSWIR
Read more →INMNASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Pharmaceuticals Increases Cannabinoid Yield to 5 g/L with IntegraSyn in A
InMed Pharmaceuticals Increases Cannabinoid Yield to 5 g/L with IntegraSyn in Advance of Commercial Scale Production Vancouver, BC - June 17, 2021 - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (Nasdaq: INM), a clinical-stage company developing cannabinoid-based phar
Read more →INMNASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Pharmaceuticals to Present at the 2021 BIO Digital Conference Vancouver,
InMed Pharmaceuticals to Present at the 2021 BIO Digital Conference Vancouver, BC - June 9, 2021 - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (Nasdaq: INM), a clinical-stage company developing cannabinoid-based pharmaceutical drug candidates and leading the clinica
Read more →INMNASDAQ:INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Pharmaceuticals Reports Third Quarter Fiscal 2021 Financial Results Vancou
InMed Pharmaceuticals Reports Third Quarter Fiscal 2021 Financial Results Vancouver, BC - May 13, 2021 - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ:INM), a clinical-stage company developing pharmaceutical-based drug candidates and leading the way in the cli
Read more →INMTSX:IN NASDAQ:INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Pharmaceuticals to Report Third Quarter Fiscal 2021 Financial Resul
Pharmaceuticals to Report Third Quarter Fiscal 2021 Financial Results BC - May 6, 2021 - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ:INM; TSX:IN), a clinical-stage company developing pharmaceutical-based drug candidates and leading the way in the clinical deve
Read more →INMTSX:IN NASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed to Present at Canaccord Genuity's 5th Annual Global Cannabis Confe
InMed to Present at Canaccord Genuity's 5th Annual Global Cannabis Conference on May 11th, 2021 Vancouver, BC - May 4th, 2021 - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (Nasdaq: INM; TSX:IN), a clinical-stage company developing cannabinoid-based pharmaceutical dr
Read more →INMTSX:IN NASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Pharmaceuticals Submits Clinical Trial Applications to Evaluate IN
Pharmaceuticals Submits Clinical Trial Applications to Evaluate INM-755 (Cannabinol) Cream in a Phase 2 Trial for Epidermolysis Bullosa BC - April 28, 2021 - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (Nasdaq: INM; TSX:IN), a world leader in the clinical development
Read more →INMU N L O C K I N G T H E P O T E N T I A L O F C A N N A B I N O I D M E D I C I N E S Company Webinar April 2021 :IN :I NM *common shares to be delisted from the TSX on or about
U N L O C K I N G T H E P O T E N T I A L O F C A N N A B I N O I D M E D I C I N E S Company Webinar April 2021 :IN :I NM *common shares to be delisted from the TSX on or about May 7, 2021 www.inmedpharma.com Forward Looking Statements This presentation contains forward - looki
Read more →INMTSX: IN NASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Pharmaceuticals Achieves 2g/L Cannabinoid Yield with IntegraSyn T
Pharmaceuticals Achieves 2g/L Cannabinoid Yield with IntegraSyn yield level demonstrates commercial viability; supports advancing to large-scale production BC - April 26, 2021 - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (Nasdaq: INM; TSX:IN), a clinical-stage compa
Read more →INMTSX:IN NASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed to Present at Virtual Conferences in March 2021 Vancouver, BC - Ma
Virtual Conferences in March 2021 Vancouver, BC - March 3rd, 2021 - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (Nasdaq: INM; TSX:IN), a clinical-stage company developing cannabinoid-based pharmaceutical drug candidates targeting diseases with high unmet medical need
Read more →INMTSX:IN Nasdaq:INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Announces Closing of US$4.5 Million Private Placement Vancouver, BC
InMed Announces Closing of US$4.5 Million Private Placement Vancouver, BC - February 16th, 2021 - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (Nasdaq:INM) (TSX:IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet med
Read more →INMTSX:IN NASDAQ:INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Pharmaceuticals Reports Second Quarter Fiscal 2021 Financial Result
InMed Pharmaceuticals Reports Second Quarter Fiscal 2021 Financial Results Vancouver, BC - February 11, 2021 - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ:INM; TSX:IN), a clinical-stage pharmaceutical company developing medications targeting diseases with hi
Read more →INMTSX:IN Nasdaq:INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Announces US$4.5 Million Private Placement Vancouver, BC - February
InMed Announces US$4.5 Million Vancouver, BC - February 5th, 2021 - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (Nasdaq:INM) (TSX:IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the clini
Read more →INMTSX:IN NASDAQ:INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Pharmaceuticals to Participate in 2021 Cannabinoid-Derived Pharmace
Pharmaceuticals to Participate in 2021 Cannabinoid-Derived Pharmaceuticals Industry Review Summit Europe Michael Woudenberg, Karen Long & Prof. Mauro Maccarrone among Expert Speakers BC - January 19, 2021 - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ:INM) (TS
Read more →INMTSX:IN NASDAQ:INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Announces Results of Second Phase 1 Clinical Trial of INM-755 CBN C
InMed Announces Results of Second Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects Vancouver, BC - January 8, 2021 - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ:INM; TSX:IN), a clinical-stage pharmaceutical company developing medications targe
Read more →INMTSX:IN NASDAQ:INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed to Participate at Virtual Conferences in January 2021 Vancouver, BC
InMed to Participate at Virtual Conferences in January 2021 Vancouver, BC - January 5th, 2021 - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ:INM) (TSX:IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medic
Read more →INMU N L O C K I N G T H E P O T E N T I A L O F C A N N A B I N O I D M E D I C I N E S Corporate Presentation January 2021 www.inmedpharma.com :IN :I NM This presentation contains forward - looking statements and forward
U N L O C K I N G T H E P O T E N T I A L O F C A N N A B I N O I D M E D I C I N E S Corporate Presentation January 2021 www.inmedpharma.com :IN :I NM This presentation contains forward - looking statements and forward - looking information within the meaning of applicable secu
Read more →INMTSX:IN NASDAQ:INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Licenses MiDROPS Delivery Technology from EyeCRO for the Delivery o
InMed Licenses MiDROPS Delivery Technology from EyeCRO for the Delivery of Therapeutic Cannabinoids - Initial application with INM-088 to treat ocular disease - BC - December 3, 2020 - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ:INM; TSX:IN), a clinical-st
Read more →INMTSX:IN NASDAQ:INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Announces Results of Initial Phase 1 Clinical Trial of INM-755 CBN
InMed Announces Results of Initial Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects Vancouver, BC November 25, 2020 InMed Pharmaceuticals Inc. ( InMed or the Company ) (NASDAQ:INM; TSX:IN), a clinical-stage pharmaceutical company developing medications targeting
Read more →INMTSX:IN NASDAQ:INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Pharmaceuticals and BayMedica Announce Collaboration for Manufactur
InMed Pharmaceuticals and BayMedica Announce Collaboration for Manufacturing and Testing of Novel Cannabinoid Therapeutics Vancouver, BC November 18, 2020 InMed Pharmaceuticals Inc. ( InMed or the Company ) (NASDAQ:INM; TSX:IN), a clinical-stage pharmaceutical company developi
Read more →INMTSX:IN NASDAQ:INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Pharmaceuticals Announces the Closing of US$8 Million Public Offeri
InMed Pharmaceuticals Announces the Closing of US$8 Million Public Offering VANCOUVER, November 16, 2020 InMed Pharmaceuticals Inc. ( InMed or the Company ) (NASDAQ:INM; TSX:IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet m
Read more →INMTSX:IN NASDAQ:INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Pharmaceuticals Reports First Quarter Fiscal 2021 IFRS Financial Re
InMed Pharmaceuticals Reports First Quarter Fiscal 2021 IFRS Financial Results Vancouver, BC November 13, 2020 InMed Pharmaceuticals Inc. ( InMed or the Company ) (NASDAQ:INM; TSX:IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high
Read more →Competitive Position
How INM ranks across every disease it competes inCompetitive Position is a premium feature
See how INM ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial